{
  "trial_id": "NCT01165684",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Gender, Duration of diabetes, Basal insulin treatment duration, HbA1c level, BMI, Blood pressure, Liver function (ALAT), Renal function (serum creatinine), History of cardiovascular disease, History of severe hypoglycemia, Retinopathy status, Concomitant medication use",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Gender",
          "Gender"
        ],
        [
          "Body Mass Index (BMI)",
          "BMI"
        ],
        [
          "Glycosylated haemoglobin (HbA1c)",
          "HbA1c level"
        ]
      ],
      "remaining_reference_features": [
        "Body weight",
        "Fasting plasma glucose (FPG)"
      ],
      "remaining_candidate_features": [
        "Duration of diabetes",
        "Basal insulin treatment duration",
        "Blood pressure",
        "Liver function (ALAT)",
        "Renal function (serum creatinine)",
        "History of cardiovascular disease",
        "History of severe hypoglycemia",
        "Retinopathy status",
        "Concomitant medication use"
      ]
    },
    "processed-gen-response": "Age, Gender, Duration of diabetes, Basal insulin treatment duration, HbA1c level, BMI, Blood pressure, Liver function (ALAT), Renal function (serum creatinine), History of cardiovascular disease, History of severe hypoglycemia, Retinopathy status, Concomitant medication use"
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Serum Creatinine, Alanine Aminotransferase (ALAT), Use of Basal Insulin, Use of Oral Anti-diabetic Drugs (OADs),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Gender",
          "Sex: Female"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Glycosylated haemoglobin (HbA1c)",
          "Baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Body weight",
        "Fasting plasma glucose (FPG)"
      ],
      "remaining_candidate_features": [
        "Male",
        "Race/Ethnicity",
        "Region of Enrollment",
        "Duration of Diabetes",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Serum Creatinine",
        "Alanine Aminotransferase (ALAT)",
        "Use of Basal Insulin",
        "Use of Oral Anti-diabetic Drugs (OADs)"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Serum Creatinine, Alanine Aminotransferase (ALAT), Use of Basal Insulin, Use of Oral Anti-diabetic Drugs (OADs)"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Region of Enrollment, Diabetes Diagnosis Duration, Baseline HbA1c, BMI, Systolic Blood Pressure, Diastolic Blood Pressure, Insulin Dose, Type of Basal Insulin, Duration of Basal Insulin Treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Body Mass Index (BMI)",
          "BMI"
        ],
        [
          "Glycosylated haemoglobin (HbA1c)",
          "Baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Gender",
        "Body weight",
        "Fasting plasma glucose (FPG)"
      ],
      "remaining_candidate_features": [
        "Sex: Female",
        "Male",
        "Region of Enrollment",
        "Diabetes Diagnosis Duration",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Insulin Dose",
        "Type of Basal Insulin",
        "Duration of Basal Insulin Treatment."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Region of Enrollment, Diabetes Diagnosis Duration, Baseline HbA1c, BMI, Systolic Blood Pressure, Diastolic Blood Pressure, Insulin Dose, Type of Basal Insulin, Duration of Basal Insulin Treatment."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, BMI, duration of diabetes, HbA1c at baseline, type of basal insulin at baseline, dose of basal insulin at baseline, use of oral anti-diabetic drugs at baseline, history of cardiovascular disease, history of hypertension, history of hypoglycaemia, smoking status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Gender",
          "sex"
        ],
        [
          "Body Mass Index (BMI)",
          "BMI"
        ],
        [
          "Glycosylated haemoglobin (HbA1c)",
          "HbA1c at baseline"
        ]
      ],
      "remaining_reference_features": [
        "Body weight",
        "Fasting plasma glucose (FPG)"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "duration of diabetes",
        "type of basal insulin at baseline",
        "dose of basal insulin at baseline",
        "use of oral anti-diabetic drugs at baseline",
        "history of cardiovascular disease",
        "history of hypertension",
        "history of hypoglycaemia",
        "smoking status"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, BMI, duration of diabetes, HbA1c at baseline, type of basal insulin at baseline, dose of basal insulin at baseline, use of oral anti-diabetic drugs at baseline, history of cardiovascular disease, history of hypertension, history of hypoglycaemia, smoking status."
  }
}